BRCA1 and ovarian carcinoma: PARPi are approved drugs in some cancer entities with BRCA1/2 genomic alterations (ovarian cancer, breast cancer, pancreatic cancer and prostate cancer10, 11, 12, 13, 14) and also in ovarian cancer characterized by HRD.15